Clinical trial
A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)
NCT00084422 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2003
- Completion date
- February 28, 2011
- Enrollment
- 47 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.